Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis.

Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, Geddes J, Goodwin G, Collins G, Travis S, Peters M.

Intest Res. 2019 May 31. doi: 10.5217/ir.2018.00173. [Epub ahead of print]

2.

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.

Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C.

Clin Gastroenterol Hepatol. 2019 May 14. pii: S1542-3565(19)30523-3. doi: 10.1016/j.cgh.2019.05.013. [Epub ahead of print]

3.

The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Lynch KD, Keshav S, Chapman RW.

Curr Hepatol Rep. 2019;18(1):115-126. doi: 10.1007/s11901-019-00456-2. Epub 2019 Mar 7. Review.

4.

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis.

Walsh A, Kormilitzin A, Hinds C, Sexton V, Brain O, Keshav S, Uhlig H, Geddes J, Goodwin G, Peters M, Collins G, Travis S.

J Crohns Colitis. 2019 Mar 30;13(4):424-430. doi: 10.1093/ecco-jcc/jjy184.

PMID:
30445625
5.

Consequences of Identifying XIAP Deficiency in an Adult Patient With Inflammatory Bowel Disease.

Quaranta M, Wilson R, Gonçalves Serra E, Pandey S, Schwerd T, Gilmour K, Klenerman P, Powrie F, Keshav S, Travis SPL, Anderson CA, Uhlig HH.

Gastroenterology. 2018 Jul;155(1):231-234. doi: 10.1053/j.gastro.2018.03.069. Epub 2018 Jun 9. No abstract available.

PMID:
29894681
6.

Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices.

Irani NR, Wang LM, Collins GS, Keshav S, Travis SPL.

J Crohns Colitis. 2018 Nov 9;12(10):1151-1157. doi: 10.1093/ecco-jcc/jjy081.

PMID:
29893824
7.

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S.

J Crohns Colitis. 2018 May 14. doi: 10.1093/ecco-jcc/jjy049. [Epub ahead of print]

8.

Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care.

Tomkins S, Chapman C, Myland M, Tham R, de Nobrega R, Jackson B, Keshav S.

PLoS One. 2017 Dec 15;12(12):e0189952. doi: 10.1371/journal.pone.0189952. eCollection 2017.

9.

Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis.

Parker B, Buchanan J, Wordsworth S, Keshav S, George B, East JE.

Gastrointest Endosc. 2017 Dec;86(6):1088-1099.e5. doi: 10.1016/j.gie.2017.08.031. Epub 2017 Sep 4.

10.

Circulating and Tissue-Resident CD4+ T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation.

Hegazy AN, West NR, Stubbington MJT, Wendt E, Suijker KIM, Datsi A, This S, Danne C, Campion S, Duncan SH, Owens BMJ, Uhlig HH, McMichael A; Oxford IBD Cohort Investigators, Bergthaler A, Teichmann SA, Keshav S, Powrie F.

Gastroenterology. 2017 Nov;153(5):1320-1337.e16. doi: 10.1053/j.gastro.2017.07.047. Epub 2017 Aug 4.

11.

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788d. No abstract available.

PMID:
28586341
12.

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

13.

Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report.

Akpınar H, Çetiner M, Keshav S, Örmeci N, Törüner M.

Turk J Gastroenterol. 2017 Mar;28(2):81-87. doi: 10.5152/tjg.2017.17593. Epub 2017 Jan 25. Review.

14.

New concepts in iron deficiency anaemia.

Keshav S, Stevens R.

Br J Gen Pract. 2017 Jan;67(654):10-11. doi: 10.3399/bjgp17X688465. No abstract available.

15.

Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.

Guirgis M, Wendt E, Wang LM, Walsh A, Burger D, Bryant RV, Kent A, Adamson R, Brain O, Travis SPL, Keshav S.

J Crohns Colitis. 2017 Apr 1;11(4):460-467. doi: 10.1093/ecco-jcc/jjw174.

PMID:
27856523
16.

The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era.

Martí-Gallostra M, Myrelid P, Mortensen N, Keshav S, Travis SP, George B.

Scand J Gastroenterol. 2017 Mar;52(3):251-256. doi: 10.1080/00365521.2016.1205127. Epub 2016 Nov 18.

17.

Predicting the Individual Risk of Acute Severe Colitis at Diagnosis.

Cesarini M, Collins GS, Rönnblom A, Santos A, Wang LM, Sjöberg D, Parkes M, Keshav S, Travis SP.

J Crohns Colitis. 2017 Mar 1;11(3):335-341. doi: 10.1093/ecco-jcc/jjw159.

18.

Glucocorticoids Suppress CCR9-Mediated Chemotaxis, Calcium Flux, and Adhesion to MAdCAM-1 in Human T Cells.

Wendt E, White GE, Ferry H, Huhn M, Greaves DR, Keshav S.

J Immunol. 2016 May 1;196(9):3910-9. doi: 10.4049/jimmunol.1500619. Epub 2016 Mar 25.

19.

Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.

Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, Düker G, Bettels R, Rohrbach M, Kugathasan S, Chapel H, Keshav S, Elkadri A, Platt N, Muise AM, Koletzko S, Xavier RJ, Marquardt T, Powrie F, Wraith JE, Gyrd-Hansen M, Platt FM, Uhlig HH.

Gut. 2017 Jun;66(6):1060-1073. doi: 10.1136/gutjnl-2015-310382. Epub 2016 Mar 7.

20.

Does Disease Extent Matter when Scoring the UCEIS?

Travis S, Corte C, Keshav S.

J Crohns Colitis. 2015 Aug;9(8):694. doi: 10.1093/ecco-jcc/jjv095. Epub 2015 Jun 3. No abstract available.

PMID:
26040318
21.

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.

Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP.

Gut. 2016 Mar;65(3):408-14. doi: 10.1136/gutjnl-2015-309598. Epub 2015 May 18.

PMID:
25986946
22.

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.

Wendt E, Keshav S.

Clin Exp Gastroenterol. 2015 Apr 7;8:119-30. doi: 10.2147/CEG.S48305. eCollection 2015. Review.

23.

Ratiometric analysis of fura red by flow cytometry: a technique for monitoring intracellular calcium flux in primary cell subsets.

Wendt ER, Ferry H, Greaves DR, Keshav S.

PLoS One. 2015 Apr 2;10(3):e0119532. doi: 10.1371/journal.pone.0119532. eCollection 2015.

24.

Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis.

Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M, White L, Keshav S, Travis S.

J Crohns Colitis. 2015 May;9(5):376-81. doi: 10.1093/ecco-jcc/jjv047. Epub 2015 Mar 13.

PMID:
25770163
25.

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.

Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S.

Gut. 2015 Feb;64(2):243-9. doi: 10.1136/gutjnl-2014-308004. Epub 2014 Oct 10.

PMID:
25304132
26.

Managing intractable proctitis and the problematic pouch.

Kent A, Keshav S.

Dig Dis. 2014;32(4):427-37. doi: 10.1159/000358149. Epub 2014 Jun 23. Review.

PMID:
24969291
27.

Comparing disease activity indices in ulcerative colitis.

Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP.

J Crohns Colitis. 2014 Apr;8(4):318-25. doi: 10.1016/j.crohns.2013.09.010. Epub 2013 Oct 10.

PMID:
24120021
28.

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.

Keshav S, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, Rácz I, Hetzel D, Nielsen OH, Vermeire S, Reinisch W, Karlén P, Schreiber S, Schall TJ, Bekker P; Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group.

PLoS One. 2013;8(3):e60094. doi: 10.1371/journal.pone.0060094. Epub 2013 Mar 20.

29.

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.

Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S.

Aliment Pharmacol Ther. 2013 Apr;37(7):752-3. doi: 10.1111/apt.12245. No abstract available.

30.

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1040-8. doi: 10.1111/apt.12076. Epub 2012 Oct 14.

31.

A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts.

Leedham SJ, Rodenas-Cuadrado P, Howarth K, Lewis A, Mallappa S, Segditsas S, Davis H, Jeffery R, Rodriguez-Justo M, Keshav S, Travis SP, Graham TA, East J, Clark S, Tomlinson IP.

Gut. 2013 Jan;62(1):83-93. doi: 10.1136/gutjnl-2011-301601. Epub 2012 Jan 27.

32.

Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection.

Stoesser N, Crook DW, Fung R, Griffiths D, Harding RM, Kachrimanidou M, Keshav S, Peto TE, Vaughan A, Walker AS, Dingle KE.

J Clin Microbiol. 2011 Nov;49(11):3994-6. doi: 10.1128/JCM.05349-11. Epub 2011 Sep 21.

33.

A rare cause of bloody diarrhoea.

Culver EL, Winearls C, Roberts I, Keshav S.

Gut. 2012 Jan;61(1):94, 168. doi: 10.1136/gut.2010.212852. Epub 2011 Apr 20. No abstract available.

PMID:
21508420
34.

Gastrointestinal manifestations of Fabry disease.

Keshav S.

In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 28.

35.

Quality control in upper gastrointestinal endoscopy: detection rates of gastric cancer in Oxford 2005-2008.

Vradelis S, Maynard N, Warren BF, Keshav S, Travis SP.

Postgrad Med J. 2011 May;87(1027):335-9. doi: 10.1136/pgmj.2010.101832. Epub 2011 Jan 21.

PMID:
21257996
36.

IBD care in Europe: A comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the national UK IBD audit tool.

Cassinotti A, Keshav S, Ardizzone S, Mortensen N, Sampietro G, Fociani P, Duca P, George B, Lazzaroni M, Manes G, Warren B, Foschi D, Vago G, Porro GB, Travis S.

J Crohns Colitis. 2009 Dec;3(4):291-301. doi: 10.1016/j.crohns.2009.08.002. Epub 2009 Sep 17.

PMID:
21172290
37.

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ.

J Pharmacol Exp Ther. 2010 Oct;335(1):61-9. doi: 10.1124/jpet.110.169714. Epub 2010 Jul 21.

PMID:
20660125
38.

Polymorphism in factor VII gene modifies phenotype of severe haemophilia.

Jayandharan GR, Nair SC, Poonnoose PM, Thomas R, John J, Keshav SK, Cherian RS, Devadarishini M, Lakshmi KM, Shaji RV, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A.

Haemophilia. 2009 Nov;15(6):1228-36. doi: 10.1111/j.1365-2516.2009.02080.x. Epub 2009 Aug 16.

PMID:
19686262
39.

Addition of senna improves quality of colonoscopy preparation with magnesium citrate.

Vradelis S, Kalaitzakis E, Sharifi Y, Buchel O, Keshav S, Chapman RW, Braden B.

World J Gastroenterol. 2009 Apr 14;15(14):1759-63.

40.

Clinical challenges and images in GI. Intestinal posttransplant lymphoproliferative disorder.

Brain O, von Herbay A, Keshav S.

Gastroenterology. 2009 May;136(5):1506, 1845. doi: 10.1053/j.gastro.2008.10.034. Epub 2009 Mar 28. No abstract available.

PMID:
19332168
41.

Primary carbonatite melt from deeply subducted oceanic crust.

Walter MJ, Bulanova GP, Armstrong LS, Keshav S, Blundy JD, Gudfinnsson G, Lord OT, Lennie AR, Clark SM, Smith CB, Gobbo L.

Nature. 2008 Jul 31;454(7204):622-5. doi: 10.1038/nature07132.

PMID:
18668105
42.

Medical management of Crohn's disease.

Cummings JR, Keshav S, Travis SP.

BMJ. 2008 May 10;336(7652):1062-6. doi: 10.1136/bmj.39547.603218.AE. Review. No abstract available.

43.

Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.

Hoffmann B, Schwarz M, Mehta A, Keshav S; Fabry Outcome Survey European Investigators.

Clin Gastroenterol Hepatol. 2007 Dec;5(12):1447-53. Epub 2007 Oct 24.

PMID:
17919989
44.

Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.

Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SG.

J Clin Oncol. 2007 Sep 20;25(27):4262-9. Epub 2007 Aug 27.

PMID:
17724347
45.

A novel technique for NOD2/CARD15 genotyping using PCR-SSP.

Mayor NP, Shaw BE, Keshav S, Madrigal JA, Marsh SG.

J Immunol Methods. 2007 Oct 31;327(1-2):82-7. Epub 2007 Aug 10.

PMID:
17719603
46.

The pathogen recognition sensor, NOD2, is variably expressed in patients with pulmonary tuberculosis.

Lala S, Dheda K, Chang JS, Huggett JF, Kim LU, Johnson MA, Rook GA, Keshav S, Zumla A.

BMC Infect Dis. 2007 Aug 16;7:96.

47.

Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment.

Hoffmann B, Keshav S.

Acta Paediatr. 2007 Apr;96(455):84-6. Review.

PMID:
17391450
48.

Review article: maintenance therapy in patients with ulcerative colitis.

Orchard T, Probert CS, Keshav S.

Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:17-22. Review.

49.

Paneth cells: leukocyte-like mediators of innate immunity in the intestine.

Keshav S.

J Leukoc Biol. 2006 Sep;80(3):500-8. Epub 2006 Jun 22. Review.

PMID:
16793911
50.

Expression of mannose receptor and ligands for its cysteine-rich domain in venous sinuses of human spleen.

Martinez-Pomares L, Hanitsch LG, Stillion R, Keshav S, Gordon S.

Lab Invest. 2005 Oct;85(10):1238-49.

Supplemental Content

Loading ...
Support Center